Recombinant SARS-CoV-2 B.1.640 Spike RBD His-tag

Catalog Number: 11077-CV

DESCRIPTION

Source	Human embryonic kidney cell, HEK293-derived sars-cov-2 Spike RBD protein Arg319-Phe541 (Arg346Ser, Asn394Ser, Tyr449Asn, Phe490Arg, Asn501Tyr), with a C-terminal 6-His tag Accession # YP_009724390.1
N-terminal Sequence Analysis	Arg319
Predicted Molecular Mass	26 kDa

SPECIFICATIONS

SDS-PAGE	33-39 kDa, under reducing conditions.
Activity	Measured by its binding ability in a functional ELISA with Recombinant Human ACE-2 His-tag (Catalog # 933-ZN).
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 500 µg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	**Use a manual defrost freezer and avoid repeated freeze-thaw cycles.** • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA

Binding Activity



Recombinant SARS-CoV-2 B.1.640 Spike RBD His-tag Protein Binding Activity. Recombinant SARS-CoV-2 B.1.640 Spike RBD His-tag Protein (Catalog # 11077-CV) binds Recombinant Human ACE-2 His-tag (Catalog # 933-ZN) in a functional ELISA.

SDS-PAGE



Recombinant SARS-CoV-2 B.1.640 Spike RBD His-tag Protein SDS-PAGE. 2 µg/lane of Recombinant SARS-CoV-2 B.1.640 Spike RBD His-tag Protein (Catalog # 11077-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 33-39 kDa.

BACKGROUND

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that also include MERS and SARS-CoV-1. Coronaviruses are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N) (1). The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 (2). In SARS-CoV-2, as with most coronaviruses, proteolytic cleavage of the S protein into S1 and S2 subunits is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3-5). A metallopeptidase, angiotensin-converting enzyme 2 (ACE-2), has been identified as a functional receptor for SARS-CoV-2 through interaction with a receptor binding domain (RBD) located at the C-terminus of S1 subunit (6, 7). The RBD of SARS-CoV-2 shares 73% aa identity with the RBD of the SARS-CoV-1, but only 22% amino acid (aa) identity with the RBD of MERS. A SARS-CoV-2 variant (B.1.640 or B.1.640.1) carrying the aa substitution Arg346Ser, Asn394Ser, Tyr449Asn, Phe490Arg, and Asn501Tyr in the RBD was identified in samples from France, Indonesia, and Republic of the Congo (8). Whether these mutations in RBD would cause more severe symptom or decrease the efficacy of vaccine-induced immunity is still under investigation.

References:

1. Wu, F. *et al.* (2020) Nature **579**:265.
2. Tortorici, M.A. and D. Veesler (2019) Adv. Virus Res. **105**:93.
3. Bosch, B.J. *et al.* (2003) J. Virol. **77**:8801.
4. Belouzard, S. *et al.* (2009) Proc. Natl. Acad. Sci. **106**:5871.
5. Millet, J.K. and G.R. Whittaker (2015) Virus Res. **202**:120.
6. Li, W. *et al.* (2003) Nature **426**:450.
7. Wong, S.K. *et al.* (2004) J. Biol. Chem. **279**:3197.
8. Colson, P. *et al.* (2021) medRxiv https://doi.org/10.1101/2021.12.24.21268174.

bio-techne®
Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956
USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373
Europe | Middle East | Africa TEL +44 (0)1235 529449